middle.news
Actinogen Launches Open-Label Phase to Extend Xanamem Alzheimer’s Trial
9:08am on Wednesday 1st of April, 2026 AEDT
•
Healthcare
Read Story
Actinogen Launches Open-Label Phase to Extend Xanamem Alzheimer’s Trial
9:08am on Wednesday 1st of April, 2026 AEDT
Key Points
Open-label extension phase started with first participant treated
All former and current XanaMIA trial participants eligible for active Xanamem
Up to 25 months of treatment to assess long-term safety and efficacy
Randomised placebo-controlled phase continues with results due November 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
ACTINOGEN MEDICAL (ASX:ACW)
OPEN ARTICLE